gmail.com.2Department of Neurology, Christian Doppler Klinik, Paracelsus Medical University, Salzburg, Austria; Center for Cognitive Neuroscience, Salzburg, Austria; Public Health, Health Services Research and HTA, University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria.3Department of Science of Health, University of Catanzaro, Catanzaro, Italy.4Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, « G. Gaslini » Institute, University of Genoa, Genova, Italy.5Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy.6Department of Neuroscience, Biomedicine and Movement Science, University of Verona, Verona, Italy; Division of Neurology, « Franz Tappeiner » Hospital, Merano, Bolzano, Italy.Abstract
Epilepsy is one of the most common chronic disorders of the brain affecting around 70 million people worldwide. Treatment is mainly symptomatic, and most patients achieve long-term seizure control. Up to one-third of the affected subjects, however, are resistant to anticonvulsant therapy. Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) are severe, refractory epilepsy syndromes with onset in early childhood. Currently available interventions fail to control seizures in most cases, and there remains the need to identify new treatments. Cannabidiol (CBD) is the first in a new class of antiepileptic drugs. It is a major chemical of the cannabis plant, which has antiseizure properties in absence of psychoactive effects. This article provides a critical review of the pharmacology of CBD and the most recent clinical studies that evaluated its efficacy and safety as adjunctive treatment of seizures associated with LGS and DS.
Copyright 2019 Clarivate Analytics.
Antiepileptic drugs; Cannabidiol; Dravet syndrome; Epilepsy; Lennox-Gastaut syndrome; Neurologic disorders
PMID: 30938373 DOI: 10.1358/dot.2019.55.3.2909248 ShareLinkOut – more resourcesFull Text SourcesClarivate Analytics Supplemental Content Full text links
View the Original article